The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 20, 2025

Filed:

Dec. 18, 2018
Applicant:

Zoetis Services Llc, Parsippany, NJ (US);

Inventors:

Kirby Shawn Pasloske, New South Wales, AU;

Kai Lau, New South Wales, AU;

Sarah Jane Richardson, New South Wales, AU;

Amanda Aileen Willis, New South Wales, AU;

Assignee:

Zoetis Services LLC, Parsippany, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/69 (2017.01); A61K 9/00 (2006.01); A61K 31/05 (2006.01); A61K 31/14 (2006.01); A61K 31/403 (2006.01); A61K 31/5415 (2006.01); A61K 31/57 (2006.01); A61K 31/573 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/40 (2006.01); A61P 23/00 (2006.01); A61P 25/04 (2006.01); A61P 29/00 (2006.01); A61P 43/00 (2006.01); B82Y 5/00 (2011.01); C08B 37/16 (2006.01); C08L 5/16 (2006.01);
U.S. Cl.
CPC ...
A61K 31/573 (2013.01); A61K 9/0019 (2013.01); A61K 31/05 (2013.01); A61K 31/14 (2013.01); A61K 31/403 (2013.01); A61K 31/5415 (2013.01); A61K 31/57 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/40 (2013.01); A61K 47/6951 (2017.08); A61P 23/00 (2018.01); A61P 25/04 (2018.01); A61P 29/00 (2018.01); A61P 43/00 (2018.01); B82Y 5/00 (2013.01); C08B 37/0015 (2013.01); C08L 5/16 (2013.01);
Abstract

Injectable pharmaceutical compositions, methods of use and formulation are disclosed. The compositions comprise: one or more water soluble complexes, each complex comprising a cyclodextrin or a cyclodextrin derivative and a hydrophobic drug; at least one preservative; and at least one co-solvent. The compositions are effectively preserved in accordance with the European Pharmacopoeia 2011 Test for Efficacy of Antimicrobial Preservation, satisfying at least the B criteria as it applies to parenterals, and the United States Pharmacopeia 2011 Guidelines for Antimicrobial Effectiveness Testing, satisfying the criteria for Category 1 (injectable) products.


Find Patent Forward Citations

Loading…